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Abstract
Background: People seeking treatment for substance use disorders often have additional health and social issues.
Although individuals presenting with alcohol as the primary drug of concern (PDOC) account for nearly half of all
treatment episodes to the Australian alcohol and other drug (AOD) service system, previous treatment cohort
studies have focused only on the profile of Australian heroin or methamphetamine users. While studies overseas
indicate that clients seeking treatment primarily for their drinking are less likely to experience social and economic
marginalisation than those seeking treatment primarily for illicit or pharmaceutical drug use, very little research has
directly compared individuals presenting with alcohol as the PDOC to those primarily presenting with other drugs
as their PDOC.
Methods: Seven hundred and ninety-six participants were recruited at entry to specialist AOD treatment in Victoria
and Western Australia, and completed measures of demographic and social factors, substance use, quality of life,
service use, and criminal justice involvement. We compared those with alcohol as their PDOC to those with other
drugs as their PDOC using Pearson chi-square and Mann–Whitney U tests.
Results: Rates of social disadvantage, poor quality of life, high severity of substance dependence, and past-year
AOD, mental health, acute health, and social service use were high in all groups. However, participants with alcohol as
the PDOC were older; more likely to have an educational qualification; less likely to report criminal justice involvement,
housing/homelessness service use, tobacco smoking, or problems with multiple substances; and reported better
environmental quality of life; but were more likely to have used ambulance services, than those with other drugs
as their PDOC.
Conclusions: While those seeking treatment primarily for alcohol problems appear less likely to suffer some forms of
social and economic disadvantage or to use multiple substances than those with a primary drug problem, they
experience similarly high levels of substance dependence severity and mental health and AOD service use. These
findings reinforce the need for AOD services to integrate or coordinate care with programs that address the many
complexities clients frequently present with, while also acknowledging differences between those seeking treatment
for alcohol versus other drug problems.
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Background
The significant health harms and social costs associated
with alcohol and other drug (AOD) use disorders are
well-documented [1–4]. However, recent studies from
Australia indicate that less than a quarter of people with
an alcohol use disorder in the past year seek any type of
mental health treatment [5], while rates of help-seeking
among young people with substance use disorders are
even lower [6]. The stigmatisation involved in seeking
help for AOD problems [7] contributes to low levels of
help-seeking for these disorders, and leads people to
delay help-seeking until their substance use problems
begin to affect multiple domains of their lives. Thus,
when people do seek treatment, they often present with
additional health and social issues, including mental
health disorders, unemployment, unstable housing and
criminal justice involvement [8–13], highlighting the
need for coordinated inter-agency responses.
A small number of studies suggest that clients seeking
treatment primarily for their drinking are less likely to
experience social and economic marginalisation than
those seeking treatment primarily for illicit or pharma-
ceutical drug use. For example, a recent large study from
Singapore (n = 563) found higher rates of marriage and
employment and better quality of life among individuals
presenting for alcohol problems compared to those with
other drug problems [14]. Similar findings were reported
by Stenius and colleagues [15] in their analysis combining
data from AOD treatment clients from Contra Costa
County, California and Stockholm, Sweden. The authors
categorised participants as “marginalised” (no stable hous-
ing; no employment, study, or household duties; and no
social networks other than those mainly composed of
people with substance use problems), “integrated” (having
both stable housing and either employment, study, or
household duties), and “intermediate” (having either stable
housing or either employment, household duties, or study-
ing, but not both). In both study settings (Sweden and
California), marginalised and intermediate participants
were more likely than integrated participants to be
dependent on drugs other than alcohol, while in Sweden,
the integrated participants were more likely than margina-
lised participants to be heavy/dependent drinkers. While
these data suggest alcohol problems are associated with
less social marginalisation than other drug problems, an
analysis of mortality rates among AOD treatment service
clients following treatment in the Australian state of
Victoria found that those with alcohol as the primary drug
of concern (PDOC) had higher post-treatment mortality
rates than clients with any other PDOC, even after con-
trolling for their older age and other demographic differ-
ences [16]. This suggests that those with alcohol as their
PDOC may experience particularly severe health prob-
lems, relative to those with other drug problems.
Publicly-available AOD treatment statistics from
England and Australia also suggest demographic differ-
ences between clients presenting primarily with alcohol
problems and those with other drug problems. In
England in 2014–15, clients seeking treatment for alco-
hol only were, on average, older than the English median
age, while clients seeking treatment for illicit drug use,
or for a combination of alcohol and illicit drug use, were,
on average, below the English median age. Men com-
prised the majority in all groups, although were a lower
proportion among those seeking treatment for alcohol
only (62 % vs. 73–75 % in illicit drug-using groups).
Similar to the findings of less marginalisation in Sweden
and Singapore, alcohol-only clients in England were less
likely to report housing problems compared with clients
with other drug problems [17]. Consistent with these
findings, data on AOD treatment episodes in 2012–13 in
Australia [18] highlight alcohol as more commonly being
the PDOC among older age groups than among younger
treatment entrants and, relative to clients for whom can-
nabis, amphetamines, or heroin was the PDOC, those
with alcohol as the PDOC included a larger proportion
of female clients. In addition, those with alcohol as the
PDOC were more likely to be Aboriginal or Torres Strait
Islander and less likely to report secondary drugs of con-
cern. Alcohol was also more likely to be the PDOC in
remote areas than in major cities.
In the Australian publicly-funded AOD treatment sys-
tem, substance use is assessed and treated within a sin-
gle specialist service system, with clients usually treated
by the same workforce within the same services regard-
less of their PDOC. Treatment may include outpatient
counselling, withdrawal management (in a residential
detoxification facility or home-based), rehabilitation
(usually residential), information/education interven-
tions, or case management to support other health and
welfare needs. Opiate substitution pharmacotherapy is
offered by AOD specialist treatment services in some
Australian states, but is primarily accessed through pri-
mary health care services (i.e. general practitioners). The
most common PDOCs among clients accessing publicly
funded AOD specialist treatment services in Australia
are alcohol and cannabis (equating to 41 and 24 % of
treatment episodes, respectively in 2012–2013), followed
by amphetamines (14 %) and opioids (13 %) [18]. In con-
trast, the two largest Australian treatment outcome
studies conducted to date primarily focussed on clients
with problematic opioid [12] or meth/amphetamine use
[19], and the characteristics of those presenting for treat-
ment for alcohol or cannabis use within the Australian
system has received little research attention. It remains
unclear whether differences in the “marginalisation pro-
file” found between alcohol-dependent and other drug-
dependent clients in Sweden, Singapore and the US
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generalise to Australia, and to what degree health and
other factors (e.g., poor health, criminal involvement)
further complicate presentations to the AOD system.
Moreover, while international studies have shown high
rates of acute health service use [20, 21], broader health
and welfare service system use by this population has
not been examined in detail in Australian treatment co-
hort studies to date.
In the Patient Pathways study, we aimed to address
these issues by interviewing clients from AOD services in
two Australian states at treatment entry to assess their
pathways into treatment, service use, and the nature and
severity of their problems. In this paper, we describe char-
acteristics of participants at the baseline interview, with a
specific focus on differences between those reporting
alcohol, as opposed to other drugs, as their PDOC. Based
on treatment cohort studies internationally, and recent
Australian treatment data, we expected those reporting al-
cohol as their PDOC would be older, less socially margina-
lised (i.e. more likely to be employed, to have educational
qualifications, to be in a relationship) and to therefore re-
port a higher social and environmental quality of life, as
well as being less likely to report problems with additional
substances, than those reporting other drugs as PDOCs.
Given the different legal status of alcohol compared with
most other commonly-used drugs, we also predicted that
those with alcohol as the PDOC would report lower rates
of legal problems. We expected these differences to also
be reflected in lower rates of use of certain types of social
services, including housing, employment, and legal aid
services, among those with alcohol as the PDOC. How-
ever, given previous findings of higher mortality rates in
those with alcohol as the PDOC, we also expected they
would report a higher rate of health service use.
Method
Participants and procedure
AOD treatment services in Victoria and Western Australia
(WA) were purposively selected as recruitment sites to
represent major treatment types. In selecting agencies,
both metropolitan and regional locations were included,
with a preference for agencies with a substantial client
load and offering two or more treatment types. Of 21
organisations approached for participation, all but one
agreed to be involved.
Baseline interviews were conducted between January
2012 and January 2013. Interviews were conducted face-
to-face (except in 11 cases where distance necessitated a
telephone interview) by trained researchers. Clients were
eligible for the study if they were at least 18 years of age;
had been assessed for, or commenced, their primary
index treatment (PIT) episode in the past month; and
had not engaged in the same treatment in the three
weeks prior to commencing the current treatment
episode. In total, 1054 clients were referred to the study
for screening, of whom 796 (75.5 %) met inclusion cri-
teria, provided written informed consent, and completed
the baseline interview. Of the remainder, 81 were found
to be ineligible, 26 declined to participate, 1 was deceased,
and 150 could not be contacted. Of the final sample of
796 people, there were 214 whose PIT was outpatient
treatment (assessment n = 29, outpatient counselling
n = 170, pharmacotherapy n = 15); 352 whose PIT was
withdrawal management (inpatient detoxification n = 346,
home-based detoxification n = 6); and 230 whose PIT was
longer-term residential rehabilitation or engagement in a
therapeutic community. Participants were reimbursed $25
for the baseline interview, which took an average of one
hour. Ethical approval for the study was obtained from
Research Ethics Committees at Eastern Health, Monash
University, and Curtin University.
Measures
Demographic and social variables included age, sex,
country of birth, Aboriginal or Torres Strait Islander sta-
tus, employment, income support payment received,
housing and legal status. Participants were asked what
primary drug of concern (PDOC) brought them to treat-
ment and whether they had any secondary drugs of con-
cern (SDOCs). Dependence on the PDOC was measured
using the Severity of Dependence Scale (SDS), which
provides a continuous measure that can differentiate se-
verity of dependence, and has been validated in samples
of substance users in Australia and internationally [22].
Quality of life (QOL) was measured using the World
Health Organisation Quality of Life brief scale (WHO-
QOL-BREF), which has four domains: psychological,
physical, social, and environmental [23].
Participants were asked whether they had accessed
AOD (counselling, withdrawal, rehabilitation, and other),
health (general practitioner (GP), ambulance, emergency
department, hospital inpatient admission, or outpatient
mental health), and community (employment, housing/
homelessness, legal aid, financial counselling, family/re-
lationship counselling, and other) services in the past
year. Using an adapted version of the Lifetime Drug Use
History [24], participants were asked to record number
of attendances/visits for each service type accessed in
the past 12 months. Criminal justice involvement was
also recorded in this way.
Statistical analyses
We conducted analyses using SPSS version 22. Partici-
pants were grouped according to their PDOC. Partici-
pants who nominated tobacco as their PDOC (n = 8)
were categorised according to their second DOC, be-
cause the specialist AOD treatment system does not typ-
ically treat tobacco as the main PDOC, and we therefore
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assumed that those participants were primarily receiving
treatment for their SDOC. Our primary analyses com-
pared participants with alcohol as their PDOC to those
with other drugs as their PDOC. Additionally, we con-
ducted pairwise comparisons of those with alcohol as
their PDOC to the other 3 main categories of PDOCs:
cannabinoids (cannabis and synthetic cannabinoids), opi-
oids (heroin and pharmaceutical opioids), and stimulants
(amphetamines, ecstasy, and cocaine). Pearson chi-
square tests were used for categorical variables. All con-
tinuous variables (age, SDS scores, WHOQOL scores,
and number of GP attendances) had non-normal distri-
butions (Kolmogorov-Smirnov ps < .001), so descriptive
data for these variables are expressed as medians and
inter-quartile ranges, and between-group differences in
these variables were analysed with Mann–Whitney U
tests. Because large sample sizes, such as ours, may
allow minor differences between groups to reach con-
ventional criteria for statistical significance, we instead
interpreted between-group differences according to effect
size (ES) indices (Cramer’s V for chi-square tests; r for
Mann–Whitney U tests), applying conventional criteria
for ES description (0.1 = small; 0.3 =medium; 0.5 = large).
We chose to only interpret differences with ES > 0.1 as
being substantial, which is a more conservative approach
than using the conventional criterion of p < .05: all differ-
ences in our analyses with ES > 0.1 had p < .05, but not all
differences with p < .05 had ES > 0.1.
Due to our sampling strategy, withdrawal and long-term
residential types of treatment were over-represented, and
assessment and counselling under-represented, relative to
the actual frequency of these treatment types in the spe-
cialist AOD treatment system in Victoria and WA. There-
fore, weightings based on PIT type were applied to
analyses so that results would be more generalisable to the
population receiving the treatment types sampled in these
states. These were calculated according to the proportions
of closed treatment episodes (for those accessing treat-
ment for their own AOD use only) of the treatment types
of assessment, counselling, withdrawal, and rehabilitation
in 2011–12 for all treatment provided in Victoria and WA
reported in the Alcohol and Other Drug Treatment Ser-
vices National Minimum Data Set [25]. This treatment
episode data does not include numbers of episodes with
pharmacotherapy as the main treatment type in Victoria
or WA, and opioid substitution pharmacotherapy is typic-
ally accessed through GPs, rather than the specialist AOD
treatment system, in these states, so the 15 participants
who reported this PIT type were excluded from weighted
analyses (it should be noted, however, that of the
remaining participants with opioids as their PDOC,
45.9 % were prescribed opioid substitution pharmacother-
apy at the time of their interview). The size of the sample
analysed in this report was therefore 781.
Results
Participants reported the following PDOCs (unweighted
ns, weighted/unweighted percentages): alcohol (n = 375,
46.0 %/48.1 %); cannabis (n = 117, 17.8 %/15.0 %); syn-
thetic cannabinoids (n = 2, 0.1 %/0.3 %); heroin (n = 76,
11.3 %/9.7 %); painkillers (n = 15, 2.3 %/1.9 %); bupre-
norphine (n = 6, 1.0 %/0.8 %); methadone (n = 5, 0.9 %/
0.6 %); other/unspecified opioids (n = 6, 0.7 %/0.8 %);
meth/amphetamine (n = 155, 17.1 %/19.9 %); cocaine
(n = 3, 0.4 %/0.4 %); ecstasy (n = 1, 0.4 %/0.1 %); ben-
zodiazepines (n = 8, 0.5 %/1.0 %); GHB (n = 2, 0.1 %/
0.3 %); solvent/volatile inhalants (n = 1, 0.1 %/0.1 %),
and tobacco (n = 8, 1.4 %/1.0 %). PDOC was missing
for one participant. After classifying the 8 participants
who nominated tobacco as their PDOC according to
their second DOC (alcohol: n = 3; cannabis: n = 1; her-
oin: n = 2; meth/amphetamine: n = 2), the final cat-
egories used for between-group analyses were alcohol
(n = 378, 46.4 %/48.5 %) and other drugs (n = 402,
53.6 %/51.5 %), with the main sub-groupings of other
drugs being cannabinoids (n = 120, 18.0 %/15.4 %);
opioids (n = 110, 16.7 %/14.1 %), and stimulants (n = 161,
18.2 %/20.6 %).
Representativeness of the sample
Weighted characteristics of the sample were compared
to data on all publicly-funded Australian closed counsel-
ling, assessment, withdrawal, and rehabilitation treat-
ment episodes for drug use in 2011–12 [25] on variables
that were available to analyse from the latter dataset, to
estimate the degree to which our sample was representa-
tive of the overall Australian population seeking AOD
treatment types included in our sample. As shown in
Table 1, our sample appeared to be closely representative
in terms of age (except for the youngest age group, due
to our exclusion of participants aged under 18) and
PDOC, but contained somewhat fewer males and Abori-
ginal or Torres Strait Islanders than would be expected
if we had recruited a random sample from all Australian
states and territories.
Demographic characteristics
Demographic, socio-economic, and legal characteristics
of the sample are shown in Table 2. The majority of the
sample was male. Only those with opioids as their
PDOC were substantially more likely to be male than
those with alcohol. Those with alcohol as their PDOC
were older, both when compared to other PDOCs over-
all, and compared to each specific drug category, with
most differences having ES in the medium-large range.
Most participants were Australian born. Only those with
stimulants as their PDOC were substantially more likely
to be born in Australia than those with alcohol as their
PDOC.
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Table 1 Comparison of key sample characteristics to 2011–12 Australian treatment episode data
Total sample (N = 781) Australian counselling, withdrawal, assessment,
and rehabilitation closed treatment episodes
for drug use in 2011–12 (N = 117,257)
Male (%) 59.6 68.0
Age
10–19 (%) 1.1 8.7
20–29 (%) 25.8 28.3
30–39 (%) 33.3 30.3
40–49 (%) 24.6 20.8
50–59 (%) 12.4 8.9
60+ (%) 2.8 2.9
Aboriginal or Torres Strait Islander (%) 4.9 12.2
Primary drug of concern (prior to re-assignment
of participants with tobacco as PDOC)
Alcohol (%) 46.0 47.8
Cannabis (%) 17.8 20.1
All opioids (%) 16.2 14.5
Stimulants (amphetamines, cocaine, or ecstasy) (%) 17.9 12.6
Nicotine (%) 1.4 1.0
Benzodiazepines (%) 0.5 1.7
Table 2 Demographic, socio-economic, and legal indicators
Total sample Alcohol All drugs other
than alcohola
Cannabinoids Opioids Stimulants
Unweighted sample N 781 378 402 120 110 161
Basic demographics
Male (%) 59.6 56.6 62.3 55.3 72.3* 61.3
Age (Median, IQR) 36.5, 29.3–46.0 41.2, 32.3–49.3 33.8**, 28.0–41.3 32.9*, 25.5–46.1 35.8*, 31.6–41.5 32.7**, 27.8–38.2
Australia born (%) 79.6 77.3 81.6 82.3 72.3 88.7*
Aboriginal/Torres Strait Islander (%) 4.9 4.7 5.1 9.2 1.5 4.3
Socio-economic indicators
Completed year 12, TAFE, university
and/or apprenticeship (%)
49.3 59.7 40.4* 34.3* 48.1* 39.4*
No employment (past 90 days) (%) 64.4 59.5 68.8 71.4* 73.1* 62.4
Current unemployment benefits (%) 39.8 33.1 45.5* 38.6 43.8 53.5*
Current sickness/disability benefits (%) 28.7 28.3 29.2 30.0 37.7 20.4
Any homelessness (past 90 days) (%) 20.8 18.2 23.1 13.1 30.8* 25.2
Criminal justice system involvement
Current criminal justice issue (%) 28.4 22.4 33.7* 23.6 40.5* 37.9*
Prison (past year) (%) 4.4 3.4 5.3 2.1 8.5* 5.6
Community-based offender program
(past year) (%)
11.0 5.4 15.8* 13.6* 23.3* 10.6
IQR inter-quartile range
Effect size (ES) of pairwise tests relative to alcohol indicated by: *ES > .1, **ES > .3
aDrugs combined includes cannabinoids, opioids, and stimulants, as well as benzodiazepines, GHB, and solvent/volatile inhalants
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Social disadvantage
Less than half of the total sample had completed higher
secondary education and/or a post-secondary or trade
qualification. In comparison, in 2011, 64 % of Australians
aged 25–64 held a vocational or higher education qualifi-
cation [26]. Approximately two thirds of participants had
not engaged in any paid employment in the past 90 days
and a large majority were receiving government income
support (mainly unemployment or disability payments) at
the time of their interview. One fifth had experienced re-
cent homelessness. However, there were several substan-
tial differences between those with alcohol as their PDOC
and those with other drugs as their PDOC, with ESs in
the small-medium range. Those with alcohol as their
PDOC were more likely than the rest of the sample to
have completed secondary or post-secondary education.
They were also more likely than those with cannabinoids
or opioids as their PDOC to have participated in paid em-
ployment in the 90 days prior to their interview, and less
likely (particularly compared to those with stimulants as
their PDOC) to be in receipt of unemployment benefits at
the time of the interview. They were also less likely than
those with opioids as PDOC to have experienced recent
homelessness.
Criminal justice system involvement
Participants were asked about current criminal justice
system involvement including: awaiting charges, trial,
sentencing, or court order; summons to appear in court;
being on bond; bail; correction orders, treatment orders,
and other court orders; parole; suspended sentences;
probation; or warrants. Over a quarter of participants
had at least one current criminal justice issue. Rates of
such problems, however, were substantially lower among
those with alcohol as their PDOC than those with other
drugs as their PDOC (particularly those with opioids or
stimulants as their PDOC). Moreover, those with alcohol
as their PDOC were approximately one third as likely as
those with other drugs as their PDOC to have been sub-
ject to a community-based offender program in the past
year, and were less than half as likely to have been impri-
soned in the past year than those with opioids as their
PDOC, with these differences having small-medium ESs.
Quality of life
WHOQOL-BREF scores are shown in Table 3. For the
sample as a whole, and for both alcohol and drug
groups, median scores on every WHOQOL-BREF do-
main were more than one standard deviation (SD) below
the Australian general population norms (using means
and SDs reported by Hawthorne, Herrman, and Murphy
[27]). Indeed, for psychological QOL, the median for the
whole sample, and for those with alcohol as their PDOC,
was over 2 SDs below the general population mean.
Nevertheless, those with alcohol as their PDOC tended
to report substantially better environmental QOL than
those with drugs as their PDOC (particularly those with
opioids as their PDOC), and also reported substantially
better physical QOL than those with opioids as their
PDOC, with the ESs for these differences being in the
small-medium range.
Substance use severity
Following Gossop et al.'s [28] designation of SDS scores
over 6 as indicative of severe dependence, Table 4 shows
that large majorities of each group were severely
dependent on their PDOC (lower quartile cut-off scores
all >6). Those with alcohol as their PDOC had substan-
tially higher scores than those with stimulants as their
PDOC. Nearly half of the sample had more than one
drug of concern, aside from tobacco. However, those
with alcohol as their PDOC were substantially less likely
than the rest of the sample to have SDOCs – indeed
those with opioids as their PDOC were approximately
twice as likely as those with alcohol as their PDOC to
have SDOCs – and were also less likely to be daily to-
bacco smokers at the time of the interview. Among
those with alcohol as a PDOC who did report SDOCs,
the majority reported cannabis as an SDOC, while opi-
oids, amphetamines, and benzodiazepines were each re-
ported by between one quarter and one third of these
participants.
Past-year service use
Proportions of participants reporting use of various ser-
vice types are shown in Table 5. Previous AOD service
use was reported by 61.7 % of the whole sample, with
outpatient counselling being the most common AOD
service type. Those with alcohol as their PDOC used
each main AOD service type at similar rates to those
with other drugs as their PDOC as a whole, though
when compared specifically with those reporting opioids
as their PDOC, reported substantially lower rates of
counselling and rehabilitation.
Approximately half of the participants had attended an
emergency department in the past year, and between a
quarter and a third reported being attended to by an
ambulance or being admitted to hospital. There were
particularly high rates of medical service use among
those with alcohol as their PDOC, although rates of
acute service use were high in all groups. Relative to
those with other drugs as their PDOC (and, particularly,
relative to those with cannabinoids or stimulants as
PDOC), those with alcohol as their PDOC were substan-
tially more likely to have been attended to by an ambu-
lance. They were also more likely to have visited a GP
than those with cannabinoids or stimulants as their
PDOC, and were substantially more likely than those
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with cannabinoids as their PDOC to have attended an
emergency department at least once in the past year.
However, participants with alcohol as their PDOC re-
ported substantially fewer GP visits than those with opi-
oids as their PDOC. This may reflect accessing of opioid
substitution pharmacotherapy by participants in the opi-
oid group, as pharmacotherapy is typically accessed
through GPs in the states in which this study was con-
ducted, but may also indicate those with opiate dependence
seeking access to pharmaceutical opioids or treatment for
complications related to unsafe injecting practices (e.g., cel-
lulitis, blood-borne viruses).
Nearly half the sample accessed outpatient mental
health services in the year prior to the interview, and
these rates were similar across PDOC groups. Highlight-
ing the frequent legal, housing, and employment prob-
lems noted in Table 2, substantial minorities reported
accessing legal aid, employment, and housing/homeless-
ness services. Consistent with their lower rates of criminal
justice system involvement and recent homelessness,
those with alcohol as their PDOC were substantially less
likely than those with other drugs as their PDOC to have
used housing or homelessness services (particularly rela-
tive to those with opioids as their PDOC) and were less
likely to have accessed legal aid relative to those with opi-
oids or stimulants as their PDOC. ESs of differences in
service use, where they existed, were all within the small-
medium range.
Table 4 Severity of dependence and secondary drugs of concern (SDOC)
Total sample Alcohol All drugs other
than alcohola
Cannabinoids Opioids Stimulants
Unweighted sample N 781 378 402 120 110 161
SDS score for PDOC: Median, IQR 10, 8–13 10, 8–13 10, 8–12 11, 8–13 11, 9–13 10*, 7–11
Two or more DOCs (other than tobacco) (%) 46.0 34.3 56.0* 51.4* 68.5** 48.6*
Alcohol as an SDOC (%) 23.0 n.a. 23.0 24.3 26.9 17.5
Cannabis as an SDOC (%) 24.1 18.3 31.6* n.a. 26.9 35.9*
Any opioid as an SDOC (%) 10.3 10.3 10.2 16.3 n.a. 4.2
Any stimulant as an SDOC (%) 16.1 8.3 26.6* 21.4* 31.5* n.a.
Any benzodiazepine as an SDOC (%) 12.4 11.4 13.3 7.9 26.0* 7.0
Dailyb tobacco smoking (%) 71.0 60.6 80.2* 83.8* 77.8* 78.2*
DOC drug of concern, SDOC secondary drug of concern, SDS severity of dependence scale, IQR inter-quartile range
Effect size (ES) of pairwise tests relative to alcohol indicated by: *ES > .1, **ES > .3
For analyses of specific substances as SDOC, participants with the substance as PDOC were excluded
aDrugs combined includes cannabinoids, opioids, and stimulants, as well as benzodiazepines, GHB, and solvent/volatile inhalants
bSmoked tobacco on the majority (i.e. 16–30) of the past 30 days
Table 3 Quality of life scoresa
Total sample Alcohol All drugs other
than alcoholb
Cannabinoids Opioids Stimulants
Unweighted sample N 781 378 402 120 110 161
Physical median, IQR −1.3, −1.9–−0.5 −1.1, −1.9–−0.5 −1.3, −1.9–−0.5 −1.3, −1.9–−0.5 −1.5*, −2.1–−0.7 −0.9, −1.9–−0.3
(50.0, 39.3–64.3) (53.4, 39.3–64.3) (50.0, 39.3–64.3) (50.0, 39.3–64.3) (46.4, 35.7–60.7) (57.1, 39.3–67.9)
Psychological median, IQR −2.1, −3.0–−0.6 −2.1, −3.0–−0.6 −1.8, −3.0–−0.6 −1.8, −3.0–−0.6 −2.1, −2.7–−0.9 −1.5, −3.0–−0.3
(41.7, 29.2–62.5) (41.7, 29.2–62.5) (45.8, 29.2–62.5) (45.8, 29.2–62.5) (41.7, 33.3–58.3) (50.0, 29.2–66.3)
Social median, IQR −1.2, −2.6–−0.7 −1.2, −2.6–−0.7 −1.6, −2.6–−0.7 −1.2, −2.1–−0.7 −1.6, −2.6–−0.7 −1.2, −2.3–−0.7
(50.0, 25.0–58.3) (50.0, 25.0–58.3) (41.7, 25.0–58.3) (50.0, 33.3–58.3) (41.7, 25.0–58.3) (50.0, 30.5–58.9)
Environmental median, IQR −1.2, −2.2–−0.2 −1.2, −1.9–0.0 −1.4*, −2.5–−0.7 −1.2, −2.4–−0.5 −1.9*, −2.9–−1.2 −1.2, −2.4–0.0
(59.4, 46.9–71.9) (59.4, 50.0–75.0) (56.2, 43.0–65.6) (59.4, 43.8–68.8) (50.0, 37.8–59.4) (59.4, 43.8–75.0)
IQR inter-quartile range
Effect size (ES) of pairwise tests relative to alcohol indicated by: *ES > .1
aTo clearly express degree of impairment, relative to the general population, for readers unfamiliar with the WHOQOL scale, WHOQOL scores are expressed as
Australian general population z scores (i.e. difference, in Australian general population standard deviations, from Australian general population mean, based on
Australian normative data reported by Hawthorne et al. 2006). To allow comparison with international data, scores on the commonly-used 0–100 scale are presented in
parentheses, in italics, below z scores
bDrugs combined includes cannabinoids, opioids, and stimulants, as well as benzodiazepines, GHB, and solvent/volatile inhalants
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Discussion
Consistent with previous AOD treatment cohort studies
[8, 10, 12–15], we found high rates of socio-economic
disadvantage, marginalisation, poly-substance use, and
health and social service use among people entering
publicly-funded AOD treatment in two Australian states.
These findings included low rates of educational attain-
ment and employment, a majority of participants reliant
on government benefits, and a significant minority suf-
fering homelessness and involvement with the criminal
justice system. Participants reported substantially poorer
quality of life, relative to Australian norms. A majority
had used some additional form of AOD treatment in the
previous year, suggesting that chronic or relapsing sub-
stance use problems were the norm in this cohort. A
majority had also attended acute health services, while
nearly half had accessed mental health treatment, and
substantial minorities had accessed legal aid and em-
ployment services.
These problems were pervasive across the PDOC
groupings, suggesting at least some degree of similarity
regardless of the PDOC. However, participants with al-
cohol as their PDOC, who comprised nearly half of the
sample, differed in several important ways from partici-
pants for whom other drugs were the primary problem.
As we expected, those with alcohol as the PDOC were
substantially older than other drug groups and, consist-
ent with previous reports from Singapore and Sweden
[14, 15], appeared less likely to be socio-economically
disadvantaged or marginalised. They were more likely
than all other groups to have completed higher second-
ary or tertiary education or a trade qualification and
were less likely to be receiving unemployment benefits
(though rates of unemployment benefits were still very
high in this group compared to the general population).
They were also less likely to have current criminal just-
ice issues or to have served a community-based sentence
in the past year. Their lower rate of use of housing/
homelessness services in the past year suggests that
stable housing was also more common for those with
alcohol as their PDOC. Their higher environmental
quality of life is likely related to their reduced rates of
socio-economic disadvantage, as this scale largely mea-
sures living conditions and access to services.
Participants with alcohol as their PDOC were also sub-
stantially less likely to report multiple substances of con-
cern. While a majority of those for whom other drugs
were the PDOC had multiple DOCs, nearly two thirds of
the alcohol group had no additional substance of con-
cern (other than tobacco). Moreover, while a majority of
those reporting alcohol as their PDOC were daily to-
bacco smokers, this was still a substantially lower pro-
portion than among any other group. Consistent with
available data on AOD treatment episodes in Australia,
these data suggest that poly-substance use is much more
common among those seeking treatment for use of
Table 5 Past year service use
Total sample Alcohol All drugs other
than alcohola
Cannabinoids Opioids Stimulants
Unweighted sample N 781 378 402 120 110 161
AOD services
AOD Counseling (%) 49.0 46.3 51.3 50.0 57.7* 45.5
Withdrawal (%) 27.2 27.0 27.3 24.1 30.8 27.5
Residential rehabilitation (%) 7.2 6.6 7.9 2.8 14.6* 6.3
Acute medical services
Ambulance (%) 31.2 37.0 26.1* 22.9* 34.9 21.1*
ED (%) 50.7 54.3 47.5 35.0* 57.7 50.0
Hospital inpatient (%) 27.9 29.2 26.9 29.1 29.2 22.5
GP (%) 92.4 95.0 89.9 86.4* 97.7 86.5*
Median GP visits, IQR 7, 4–13 7, 4–12 7, 4–15 6, 3–12 12*, 5–20 6, 2–12
Other community services
Outpatient mental health service (%) 45.0 42.7 47.0 48.2 48.8 43.3
Legal aid (%) 30.0 25.1 34.2 27.1 36.9* 38.7*
Employment service (%) 40.9 39.7 42.0 40.0 50.0 35.9
Housing/homelessness service (%) 23.4 18.0 28.0* 26.1 30.2* 26.8
AOD alcohol or other drugs, PIT primary index treatment, ED emergency department, GP general practitioner, IQR inter-quartile range
Effect size (ES) of pairwise tests relative to alcohol indicated by: *ES > .1
aDrugs combined includes cannabinoids, opioids, and stimulants, as well as benzodiazepines, GHB, and solvent/volatile inhalants
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drugs other than alcohol, and is less likely to be reported
when the PDOC is alcohol.
Despite their apparently lower rates of socio-economic
disadvantage, marginalisation, and poly-substance use,
participants with alcohol as the PDOC reported similarly
poor social, physical, and psychological quality of life rat-
ings as those given by other groups. In particular, psy-
chological quality of life was very low in a majority of
participants, both in the alcohol group and in the sample
more generally. Taken together with the high rate of
mental health service use, which was also similar across
groups, these findings are consistent with the high rates
of psychiatric comorbidity highlighted within previous
AOD treatment studies [5, 8, 10–12]. In addition to
mental health problems, high levels of significant phys-
ical health problems were also indicated by the high
rates of past year acute health service use, with those
reporting alcohol as their PDOC substantially more
likely to have been attended by an ambulance than the
rest of the sample. This higher rate of ambulance attend-
ance, along with Lloyd et al.'s [16] finding of higher
post-treatment mortality rates in clients with alcohol as
the PDOC, suggests particularly severe health problems
within this group. Moreover, despite their lower rates of
poly-substance problems, those with alcohol as their
PDOC reported similarly high severity of dependence to
other groups – indeed substantially higher than the SDS
scores reported by those with stimulants as their PDOC
– and all groups reported similarly high rates of past
year AOD service use.
While the focus of our analyses were on those with al-
cohol as their PDOC, it is important to note that those
with opioids as their PDOC stood out as particularly se-
vere/marginalized on a range of measures. The opioid
group reported especially high rates of recent homeless-
ness, criminal justice involvement, secondary drugs of
concern (including much higher rates of problems with
benzodiazepines than other groups), past-year AOD ser-
vice use, number of GP visits, and poorer physical and
environmental quality of life. These findings are consist-
ent with previous reports of high rates of health and
AOD service use, benzodiazepine use, criminal activity,
and physical health problems among Australian opioid
users [12, 29]. While opioid use has not received the
level of public attention that methamphetamine has
received in recent years, our results, together with
Australian treatment episode data [18], emphasise that
opioid use problems are still reported by a substantial
proportion of those entering AOD treatment, with a
multi-faceted approach likely to be required to address
their physical health, housing, and legal problems, in
addition to their substance use.
The differential findings by PDOC are likely to reflect
two main dimensions of difference between drug classes
and those who use them. One is the social position of
substance use in Australian society. Use of alcohol is dif-
ferentiated from non-medical use of other PDOCs not
only by its legality, but also by a wide acceptance of use,
and of relatively heavy use by young adults. For example,
in objecting to an official drinking guideline suggesting
an upper limit of four drinks on any occasion, Tony
Abbot, then the Minister of Health, spoke in 2008 of a
“moral panic”, noting that “what an individual does is
his or her responsibility, particularly with something that
is legal … We need to know the real enemy, and that is
illicit drugs” [30]. In Australian and cognate cultures,
adults are expected to cut down their drinking only as
they move on in their late 20s to a settled career and
forming a family [31], while illicit drug use by young
adults is to some extent furtive and much less widely ac-
cepted – particularly for heroin and other illicit opiate
use. Young people habitually using illicit drugs are thus
more likely to encounter informal and formal pressures
to enter treatment for drug use, while such pressures
concerning habitual heavy use of alcohol normatively
occur when they are as much as a decade older. The
greater marginalisation of those with illicit drugs as
PDOC reflects the selective effects of stigmatisation as-
sociated with criminal law and other deterrence [7]. The
second dimension of differentiation is that heavy use of
alcohol is in many ways more harmful to health than
heavy use of most illicit drugs [32, 33]. The multiple
health risks of heavy drinking are likely to be a substan-
tial factor in the high rates of GP, ambulance, and emer-
gency department attendance, particularly relative to
those with cannabinoids and stimulants as their PDOC.
Nevertheless, most differences between those with al-
cohol as their PDOC and those with other drugs as their
PDOC had ESs that, according to conventional criteria,
would be considered small or medium in magnitude.
Thus, while it appears that real differences exist at the
group level, there is likely to be considerable overlap in
the characteristics of individuals primarily seeking treat-
ment for alcohol and other drugs. It is also possible that
the differences between groups may be more related to
other differences (e.g. in socio-economic status, poly-
substance use, health, or access to services) that correl-
ate with the PDOCs, rather than to the PDOC itself.
There are a number of limitations to consider when
reviewing these findings. Despite the use of validated
scales, the study relied on participant self-report, with
no objective measures of substance use or verification of
service use. In addition, while the sample was large and
purposively sampled from a diverse range of treatment
services across two states, there was an over-sampling of
residential clients, which we attempted to correct in the
present analyses by applying weights based on treatment
type. This was not a random sample, and selection bias
Lubman et al. BMC Psychiatry  (2016) 16:250 Page 9 of 11
may therefore have influenced our findings. Selection
bias may also have arisen from our inability to assess all
eligible participants: of 972 clients referred to the study
who were not found to meet exclusion criteria, 18 %
could not be contacted or declined to participate, and
we do not know how many additional clients of these
services were not referred by treatment staff for screen-
ing. It is possible that those who were referred, were
contactable, and agreed to participate may represent a
more stable end of the spectrum of problem severity.
Comparison to Australian treatment data suggests that
the sample was representative in terms of PDOC and
age (aside from the exclusion of clients aged under
18 years), but may have contained less males and less
Aboriginal or Torres Strait Islander participants than
would have been expected in a random sample recruited
from all Australian states and territories. As we could
only assess the representativeness of the sample on these
variables, there may have been other unmeasured variables
that could have biased analyses and reduced generalisabil-
ity to Australian AOD treatment-seekers. Nevertheless,
the findings are consistent with previous studies examin-
ing clients in AOD treatment, with Patient Pathways being
the largest treatment cohort study to compare alcohol to
other drug treatment-seekers recruited from within the
same service system across many variables. The inclusion
of multiple measures relating to each type of social disad-
vantage corroborates findings within the study (e.g. differ-
ences in criminal justice problems and homelessness were,
to some extent, reflected in differences in legal aid and
housing service use).
Conclusions
Individuals with alcohol as their PDOC comprise nearly
half of AOD treatment clients and tend to experience
less socio-economic marginalisation and poly-substance
use than those with other drugs as their PDOC. How-
ever, their poor psychological health and elevated rates
of ambulance and GP attendances may suggest greater
health problems. Moreover, their older age, relative to
those with other drugs as the PDOC, suggests a longer
period of problematic use and accumulated health is-
sues, which is likely to impact on treatment outcomes.
The relative social acceptability of heavy drinking in
Australia and pervasive availability of alcohol, relative to
illicit drugs, may also make it more difficult for heavy
drinkers to identify problems earlier, to seek treatment
for such problems, or to maintain changes in drinking
behaviour following treatment.
In summary, the present study provides further sup-
port for the complexity and severity of AOD treatment
presentations. It also provides unique evidence within an
Australian setting that clients with alcohol as their
PDOC may differ in terms of their characteristics to
those with other drugs as their PDOC. However, similar-
ities across PDOC groups highlight that treatment still
needs to be responsive to the broad range of issues faced
by clients entering AOD treatment. Indeed, these find-
ings reinforce previous calls [34, 35] regarding the need
for integration or coordination of care between AOD
treatment programs and services that address the broad
range of complexities clients frequently present with
(e.g. housing, employment, legal aid, medical, and men-
tal health services, among others).
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